Get a weekly digest of the latest psychedelic research, new studies, and platform updates delivered to your inbox.
No spam, ever. Unsubscribe anytime.
16 million people affected globally. Over 100,000 opioid overdose deaths annually in the US alone (2021-2023). The opioid crisis is one of the most severe public health emergencies in modern history.
MAT: buprenorphine (Suboxone), methadone, naltrexone (Vivitrol). Behavioral therapies. MAT is effective but requires long-term maintenance, and access remains limited.
Ibogaine is the primary psychedelic candidate for opioid addiction. A single flood dose (15-20mg/kg) can dramatically reduce or eliminate withdrawal symptoms and cravings within hours. CRITICAL SAFETY CONCERN: Ibogaine carries significant cardiac risk (QT prolongation, fatal arrhythmia) and requires ICU-level monitoring.
Brown & Alper (2018): 50% abstinent at 12 months in observational study. Noller et al. (2018): Significant reduction in SOWS withdrawal scores. No Phase 3 RCTs completed yet.